Insights

Here’s why the Resonance Health (ASX:RHT) share price rocketed

The Resonance Health share price rocketed more than 16% today before closing 5% higher. We take a look at what’s stirring investor interest.
The post Here’s why the Resonance Health (ASX:RHT) share price rocketed appeared first on The Motley Fool Australia. –

increase in asx medical software share price represented by doctor making excited hands up gesture

The Resonance Health Ltd (ASX: RHT) share price rocketed more than 16% today before closing 5% higher.

The booming share price moves come after the company emerged from a trading halt late this morning. This follows the release of an announcement on its medical device.

What did Resonance Health report to send its shares higher?

In a late morning ASX release, Resonance Health announced that it has received Australian Therapeutic Goods Administration (TGA) approval for its HepaFat-AI device. The device provides fully automated artificial intelligence software to assesses liver fat.

With the TGA approval, Resonance Health can now supply its device across Australia. The company had already received clearance from the United States Food & Drug Administration (FDA) in early December.

HepaFat-AI automatically analyses magnetic resonance imaging (MRI) data. Subsequently, this data assesses liver fat in patients to give physicians a new tool in assessing patients with confirmed or suspected fatty liver disease.

According to Resonance Health, doctors can use the device to monitor patients for a number of issues. This will include patients in weight loss programs and screening the livers of live donors for transplant suitability. Additionally, the device will monitor patients who have or are believed to have non-alcoholic fatty liver disease (NAFLD) or the more serious subtype, non-alcoholic steatohepatitis (NASH).

Resonance Health reports that “NAFLD affects up to 2.3 billion people, a figure expected to grow year-on-year. Of these, about 470 million people (or 20%) will develop NASH”. NASH can lead to serious health consequences, including liver failure.

The company plans to market the device to radiologists and physicians involved in the routine clinical diagnosis and management of patients with confirmed or suspected fatty liver disease. However, it also sees a market with pharmaceutical companies engaged in NASH drug development.

Resonance Health says its work in machine learning to develop assistance tools for the medical sector is continuing.

Share price snapshot

Over the past 12 months, Resonance Health shares are up 2.5%. That compares to a 1% loss on the All Ordinaries Index (ASX: XAO).

Year-to-date, the Resonance Health share price is down 10.8%.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Resonance Health Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Here’s why the Resonance Health (ASX:RHT) share price rocketed appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!